Researchers use iPSCs in blood disorder studies

07/31/2013 |

Two separate studies published in the journal Blood have reprogrammed cells taken from Diamond Blackfan anemia and juvenile myelomonocytic leukemia patients and returned them to a pluripotent state. The first study used skin-derived stem cells from DBA patients and repaired the stem cells' genetic defects to allow them to mutate into sufficient quantities of red blood cells. In the second study, generated human induced pluripotent stem cells from two children with JMML were processed to produce myeloid cells that resembled JMML cells. Results showed that after testing two drug inhibitors of two different proteins that are highly active in JMML, one had reduced cancer cell development in culture. Both studies were conducted by researchers at The Children's Hospital of Philadelphia.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA